News Two Biologics Show Comparable Benefit in Uveitis by Medscape • 2026/02/10 • 0 Comments Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis. Medscape Medical News